drugset / Trial / NCT01123525

Adenosine Cardioplegia; Improved Cardioprotection?

NCT01123525

Phase 1/2 Completed 60 enrolled University Hospital of North Norway
RandomizedParallel-groupQuadruple-blindTreatment

Summary

60 elective patients for CABG will be included to receive either standard hyperkalemic cardioplegia (St.Thomas Hospital Solution No I) or cardioplegia where supranormal potassium is replaced with 1.2 mM adenosine. Hypothesis as follows: 1. Adenosine instead of supranormal potassium in the cardioplegic solution give satisfactory cardiac arrest. 2. Adenosine instead of supranormal potassium in the cardioplegic solution gives equal cardioprotection. The patients will be followed with PiCCO-catheter to monitor cardiac function and repetitive blood samples to measure release of cardiac enzymes.

Timeline

Start
2010-04
Primary completion
2011-04
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Adenosine Small molecule 1.2 mmol